It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
This study is a comparison of the efficiency of three technologies used for Y chromosome capture and the next-generation sequencing (NGS) technologies applied for determining its whole sequence. Our main findings disclose that streptavidin–biotin magnetic particle-based capture methodology offers better and a deeper sequence coverage for Y chromosome capture, compared to chromosome sorting and microdissection procedures. Moreover, this methodology is less time consuming and the most selective for capturing only Y chromosomal material, in contrast with other methodologies that result in considerable background material from other, non-targeted chromosomes. NGS results compared between two platforms, NextSeq 500 and SOLID 5500xl, produce the same coverage results. This is the first study to explore a methodological comparison of Y chromosome capture and genetic analysis. Our results indicate an improved strategy for Y chromosome research with applications in several scientific fields where this chromosome plays an important role, such as forensics, medical sciences, molecular anthropology and cancer sciences.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), Av. Ilustracion, Granada, Spain; Centro di Antropologia Molecolare per lo Studio del DNA Antico, Dipartimento di Biologia, Università degli Studi di Roma“Tor Vergata”, via della Ricerca Scientifica n. 1, Rome, Italy; University of Granada. Dept. of Biochemistry & Molecular Biology III - Faculty of Medicine - PTS, Granada, Spain
2 GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), Av. Ilustracion, Granada, Spain
3 Centro di Antropologia Molecolare per lo Studio del DNA Antico, Dipartimento di Biologia, Università degli Studi di Roma“Tor Vergata”, via della Ricerca Scientifica n. 1, Rome, Italy
4 GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), Av. Ilustracion, Granada, Spain; University of Granada. Laboratory of Genetic Identification, Legal Medicine and Toxicology Department, Faculty of Medicine -PTS, Granada, Spain